20 Chapter 1 58. Aerts, J.M., et al., Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A, 2008. 105(8): p. 2812-7. 59. Sado, D.M., et al., Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging, 2013. 6(3): p. 392-8. 60. Goldfarb, J.W., et al., T1-weighted magnetic resonance imaging shows fatty deposition after myocardial infarction. Magn Reson Med, 2007. 57(5): p. 828-34. 61. Pica, S., et al., Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance. J Cardiovasc Magn Reson, 2014. 16: p. 99. 62. Thompson, R.B., et al., T(1) mapping with cardiovascular MRI is highly sensitive for Fabry disease independent of hypertrophy and sex. Circ Cardiovasc Imaging, 2013. 6(5): p. 637-45. 63. Nordin, S., et al., Cardiac Phenotype of Prehypertrophic Fabry Disease. Circ Cardiovasc Imaging, 2018. 11(6): p. e007168. 64. Augusto, J.B., et al., The myocardial phenotype of Fabry disease pre-hypertrophy and pre- detectable storage. Eur Heart J Cardiovasc Imaging, 2020. 65. Rob, D., et al., Heart failure in Fabry disease revisited: application of current heart failure guidelines and recommendations. ESC Heart Fail, 2022. 66. Spinelli, L., et al., Does left ventricular function predict cardiac outcome in Anderson-Fabry disease? Int J Cardiovasc Imaging, 2021. 37(4): p. 1225-1236. 67. Nordin, S., et al., Proposed Stages of Myocardial Phenotype Development in Fabry Disease. JACC Cardiovasc Imaging, 2018. 68. Niemann, M., et al., Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment. JACC Cardiovasc Imaging, 2011. 4(6): p. 592-601. 69. Olivotto, I., et al., Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. J Am Coll Cardiol, 2005. 46(3): p. 480-7. 70. Treibel, T.A., et al., Sex Dimorphism in the Myocardial Response to Aortic Stenosis. JACC Cardiovasc Imaging, 2018. 11(7): p. 962-973. 71. Maceira, A.M., et al., Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson, 2006. 8(3): p. 417-26. 72. Pieske, B., et al., How to diagnose heart failure with preserved ejection fraction: the HFA- PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J, 2019. 40(40): p. 3297-3317. 73. Seydelmann, N., et al., High-Sensitivity Troponin: A Clinical Blood Biomarker for Staging Cardiomyopathy in Fabry Disease. J Am Heart Assoc, 2016. 5(6). 74. Pieroni, M., et al., Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week. J Am Coll Cardiol, 2021. 77(7): p. 922-936. 75. Akhtar, M.M. and P.M. Elliott, Anderson-Fabry disease in heart failure. Biophys Rev, 2018.10(4): p. 1107-1119.
RkJQdWJsaXNoZXIy MTk4NDMw